University of Sheffield: Encouraging Early Study for Investigational Drug in People With Motor Neurone Disease
July 11, 2020
July 11, 2020
SHEFFIELD, England, July 11 -- The University of Sheffield issued the following news:
Results from Phase 1-2 of a study published in the New England Journal of Medicine, have shown the safety and tolerability of the new investigational drug tofersen which shows the potential to reduce the levels of a toxic cell protein in people living with a form of motor neurone disease (MND); triggered by a faulty gene called SOD1 which causes the progression of the disease.
SOD1 is . . .
Results from Phase 1-2 of a study published in the New England Journal of Medicine, have shown the safety and tolerability of the new investigational drug tofersen which shows the potential to reduce the levels of a toxic cell protein in people living with a form of motor neurone disease (MND); triggered by a faulty gene called SOD1 which causes the progression of the disease.
SOD1 is . . .